title: Payers and the assessment of clinical utility for companion diagnostics.
abstract: The decision makers who approve or deny payment for health-care services review many new technologies. Reimbursement for companion diagnostics for expensive drugs ("personalized medicine") is already under close policy scrutiny, in line with long-standing concerns about overuse of diagnostic tests. Evaluation of diagnostic tests adds some complexities to the payer's comparative-effectiveness evaluation for drugs alone. Currently, decision-making frameworks suitable for companion diagnostics are being developed for practical application by payer policy makers.
authors.affiliation: Government Affairs/Life Sciences, Foley Hoag LLP, Boston, Massachusetts, USA. bquinn@foleyhoag.com
authors.forename: B
authors.initials: B
authors.lastname: Quinn
mesh_terms: D003657:Decision Making; D057069:Diagnostic Test Approval / Q000191:economics*; D006801:Humans; D057285:Precision Medicine / Q000191:economics*; D013673:Technology Assessment, Biomedical / Q000191:economics*